{"id":248778,"date":"2025-08-19T13:12:20","date_gmt":"2025-08-19T13:12:20","guid":{"rendered":"https:\/\/pharmeasy.in\/blog\/?p=248778"},"modified":"2026-04-17T12:11:10","modified_gmt":"2026-04-17T12:11:10","slug":"wegovy-semaglutide-how-it-works-who-its-for-what-to-expect","status":"publish","type":"post","link":"https:\/\/pharmeasy.in\/blog\/wegovy-semaglutide-how-it-works-who-its-for-what-to-expect\/","title":{"rendered":"Wegovy (Semaglutide): How It Works, Who It\u2019s For & What to Expect\u00a0"},"content":{"rendered":"\n\n<\/head>

Table of Contents<\/p>\nToggle<\/span>

Introduction<\/a><\/li>
How Do You Pronounce Wegovy?<\/a><\/li>
What is Wegovy?<\/a><\/li>
How Does Wegovy Work<\/a><\/li>
Who Can Use Wegovy?<\/a><\/li>
Wegovy Dosage and How to Use It<\/a><\/li>
What to Expect with Wegovy<\/a><\/li>
Wegovy Side Effects<\/a><\/li>
Wegovy Cost and Accessibility<\/a><\/li>
Warnings and Precautions<\/a><\/li>
Wegovy for Heart Health<\/a><\/li>
When to See a Doctor?<\/a><\/li>
Conclusion<\/a><\/li>
Frequently Asked Questions (FAQs)<\/a><\/li>
References<\/a><\/li><\/ul><\/nav><\/div>\n
<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\nObesity is becoming a common health issue around the world. Experts say that by 2035, more than half of the global population may be overweight or obese. Having a high body weight was linked to around 4 million deaths worldwide in 2015 ^{1<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
To help manage this problem, doctors now use a group of medicines called GLP-1 receptor agonists. This group of medicines aids in lowering blood sugar levels by increasing insulin<\/a><\/strong> and reducing glucagon<\/a><\/strong> hormones. This may help to make you feel full sooner, eat less, and lose weight ^{1<\/sup><\/a>^,<\/sup>}^{2<\/sup><\/a>. Some other GLP-1 medicines available today include}semaglutide<\/strong><\/a> (sold as Wegovy, Ozempic, and Rybelsus), tirzepatide<\/a><\/strong> (Mounjaro \u2013 a medicine that acts on both GIP and GLP1 receptors, sometimes called a \u201ctwincretin\u201d), and liraglutide<\/strong><\/a>^{2<\/sup><\/a>^,<\/sup>}^{3<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Although initially approved for treating type 2 diabetes, now certain medicines under this group like Wegovy injection are used for aiding weight loss in those who are overweight or obese along with other health problems ^{4<\/sup><\/a>^,<\/sup>}^{5<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
So, let\u2019s discuss about Wegovy (semaglutide) in this blog. We\u2019ll explain how Wegovy works, who it is for, Wegovy\u2019s side effects and how it should be taken.\u00a0<\/p>\n\n\n\n
<\/span>How Do You Pronounce Wegovy?<\/strong><\/span><\/h2>\n\n\n\nWegovy is pronounced as W\u0113-G\u014c-Vee (wee-GOH-vee). The name is broken into three parts to help pronounce it easily. By pronouncing it correctly, you can communicate clearly with your doctor or pharmacist about this medication ^{4<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
<\/span>What is Wegovy?<\/strong><\/span><\/h2>\n\n\n\nWegovy is a prescription medicine that comes as an injection. It contains semaglutide as the main ingredient. It is used to help with long-term weight management in people who are overweight or have obesity ^{4<\/sup><\/a>^,<\/sup>}^{6<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
The U.S. Food and Drug Administration (FDA), which approves medicines for safety and use, approved Wegovy in 2021 for use in adults with obesity (body mass index, BMI, of 30\u202fkg\/m\u00b2 or higher) or overweight (BMI of 27\u202fkg\/m\u00b2 or higher) plus at least one weight related health problem such as high blood pressure, high cholesterol, or type\u202f2 diabetes ^{7<\/sup><\/a>^,<\/sup>}^{8<\/sup><\/a>. It should be used along with a healthy diet and physical activity. In 2022, it was also approved for teens aged 12 years and older with obesity.
The FDA approved Wegovy in March 2024 to be used as a drug for reducing the risk of heart problems like heart attack, stroke, or death in adults who have heart disease along with obesity or overweight}^{5<\/sup><\/a>^,<\/sup>}^{10<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Wegovy and Ozempic both contain semaglutide as the main ingredient, but they are approved for different reasons. They have different dose strengths and come in different types of injection pens. Ozempic was approved in 2017 to help control blood sugar in people with type 2 diabetes, and is supplied in multidose pens, while Wegovy is for weight loss and available as single use pens ^{4<\/sup><\/a>^,<\/sup>}^{11<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Both medicines are given as a weekly injection, but the dose of Ozempic ranges from 0.5 mg to 2 mg, while Wegovy dosing is higher, 2.4 mg for weight loss ^{9<\/sup><\/a>. Let\u2019s now look in detail at how does Wegovy work.\u00a0<\/p>\n\n\n\n}
\n
Wegovy has been approved in 2022 for children who are obese above the age of 12 years. But this has to be done with a lot of caution, as sometimes in some cases, children go through bullying and peer pressure for being overweight and thus end up insisting on this drug. As per my experience, its extremely important to counsel these children first to try regular diet and lifestyle changes along with exercise, before beginning Wegovy. Parents along with the child need to be counselled regularly during the course.<\/p>\n Dr Malavika Athavale, Consulting Clinical and IBS Nutritionist<\/strong><\/a><\/cite><\/blockquote>
<\/div>

Week<\/strong>\u00a0<\/td>	Dosing<\/strong>\u00a0<\/td><\/tr>
Weeks 1\u20134\u00a0<\/td>	Wegovy 0.25 mg Flextouch\u00a0<\/a><\/td><\/tr>
Weeks 5\u20138\u00a0<\/td>	Wegovy 0.5 mg\u00a0Flextouch<\/a><\/td><\/tr>
Weeks 9\u201312\u00a0<\/td>	Wegovy 1.0 mg\u00a0Flextouch<\/a><\/td><\/tr>
Weeks 13\u201316\u00a0<\/td>	Wegovy 1.7 mg\u00a0Flextouch<\/a><\/td><\/tr>
Week 17+\u00a0<\/td>	Wegovy 2.4 mg Flextouch (or continue 1.7 mg if advised by your doctor)\u00a0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n This Wegovy dosage chart may also be modified by your doctor based on individual health condition. This injection can be taken on any day of the week, at any time, with or without food. It is usually given as an injection under the skin of the stomach, upper arm, or thigh, not in a muscle or vein. The injection site should be rotated to avoid the same spot every time.\u00a0Never take the above doses without your doctor\u2019s prescription or advice.<\/p>\n\n\n\n <\/span>What to Expect with Wegovy<\/strong><\/span><\/h2>\n\n\n\n Wegovy doesn\u2019t cause you to reduce weight suddenly. Once you start on Wegovy, you may notice slowly your weight reducing over time. Most people start seeing weight loss by week 4, but it becomes more noticeable by week 8 or later, especially after reaching the full dose (1.7\u202fmg or 2.4\u202fmg). How much weight you lose can depend on your starting weight, how regularly you take it, and your diet and activity level^{13<\/sup><\/a>.^{<\/sup>\u00a0<\/p>\n\n\n\n}} Studies show that people may lose upto 15% body weight, approximately between 6 to 12 kgs over 68 weeks when using Wegovy, when taken along with following healthy eating habits and physical activity ^{13<\/sup><\/a>.^{<\/sup>Long-terms trials are limited, but an emerging study suggests that weight loss with Wegovy can be sustained for about 4 years meaning that the effect may last if you keep using Wegovy}}^{14<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} Those without diabetes may experience greater weight loss and better results, especially when the full dose is taken regularly as advised by doctor. Also remember, Wegovy alone may not give the best result. You should continue with proper diet with low calories and engage in physical activity. So don\u2019t think it\u2019s a quick fix too, it will take some time to show result and works more effective when a healthy lifestyle is followed ^{14<\/sup><\/a>^,<\/sup>}^{15<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} \n In my opninion, the convenience of once-weekly dosing with Wegovy improves adherence significantly. And it is highly effective, however, following a structured lifestyle approach is very important alongwith and that commitment must be lifelong, with or without the medication. Even when using the medication, as gastric emptying adapts with time, patients may unconsciously increase portion sizes, leading to plateaus. Prioritising adequate protein intake (approximately 1\u20131.2 g\/kg\/day) often helps sustain progress without unnecessary dose escalation.<\/p>\nDr. Mikhil Kothari, MBBS \| PG Dip. Clinical Endocrinology & Diabetes (RCP, UK)<\/a><\/strong><\/cite><\/blockquote>\n\n\n\n <\/span>Wegovy Side Effects<\/strong><\/span><\/h2>\n\n\n\n Wegovy may cause some side effects. Most are mild, but sometimes serious problems can happen, so it\u2019s important to watch how you feel.\u00a0<\/p>\n\n\n\n \n Common Wegovy side effects include nausea, vomiting, constipation, or loose stools. These usually happen during dose escalation (over several weeks) but get better over time.\u00a0<\/li>\n\n\n\n Some people may feel belly pain, tiredness, or notice yellowing of the skin or eyes, this could be a sign of gallbladder issues such as gallstones (cholelithiasis) or gallbladder inflammation (cholecystitis), especially with rapid weight loss.\u00a0<\/li>\n\n\n\n In rare cases, side effects of Wegovy can be serious, like swelling of the pancreas (acute pancreatitis) or kidney issues (secondary to dehydration).\u00a0<\/li>\n\n\n\n People with diabetes may get low blood sugar if taking this medicine along with other diabetes medicines like sulfonylureas or insulin, which can make you feel dizzy or shaky, and may also cause sweating, confusion, or irritability.\u00a0<\/li>\n<\/ul>\n\n\n\n Wegovy has a boxed warning. It\u2019s not for people who have or had a rare thyroid cancer called medullary thyroid cancer (MTC) or a condition called MEN2. Always take Wegovy as advised by your doctor and follow their instructions carefully ^{4<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} <\/span>Wegovy Cost and Accessibility<\/strong><\/span><\/h2>\n\n\n\n Wegovy has been approved by CDSCO (Central Drugs Standard Control Organisation) in 2025 for use in obesity management and is now available through select pharmacies.\u00a0<\/p>\n\n\n\n The price varies with strength and the approximate price in India is as follows: \u2022 0.25 mg to 1 mg \u2013 \u20b917,345 per month (\u20b94,336.25 per weekly dose) \u2022 1.7 mg \u2013 \u20b924,280 per month \u2022 2.4 mg \u2013 \u20b926,015 per month\u00a0<\/p>\n\n\n\n In comparison, Wegovy costs around $1,349 (approx. \u20b91,12,365) per month in the US. In Germany, the price is approximately $328 (approx. \u20b927,300) per month, and in the Netherlands, about $296 (approx. \u20b924,640) per month ^{16<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} Other weightloss medicines are also available in India. Mounjaro (tirzepatide injection) is approved for diabetes and weight control in adults with obesity (BMI\u202f30+) or overweight (BMI\u202f27+) with related health problems like high BP, cholesterol, diabetes, sleep apnoea, or heart disease ^{17<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} Rybelsus (oral semaglutide) has the same ingredient as Wegovy but in tablet form. In India, it is approved only for type\u202f2 diabetes, not weight loss. It helps control blood sugar and can reduce the risk of heart attack or stroke in people with diabetes and heart or kidney disease ^{18<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} Other weight\u2011loss medicines like Zepbound (tirzepatide) and Ozempic (injectable semaglutide),\u00a0 are available in other countries.\u00a0<\/p>\n\n\n\n <\/span>Warnings and Precautions<\/strong><\/span><\/h2>\n\n\n\n Before your doctor starts you on Wegovy, it is important to inform the doctor if you have any of this:\u00a0<\/p>\n\n\n\n \n History of pancreatic or kidney problems<\/li>\n\n\n\n Type 2 diabetes with past vision issues like diabetic retinopathy (as Wegovy may sometimes make this worse, especially if your blood sugar improves very quickly)<\/li>\n\n\n\n Mental health conditions like depression or thoughts of self-harm<\/li>\n\n\n\n Plans for pregnancy, as Wegovy must be stopped at least two months before conception (since it stays in the body for a long time and its safety for unborn babies is not known)<\/li>\n\n\n\n Infant to breastfeed, since it is not yet confirmed if the medicine goes into breast milk\u00a0<\/li>\n<\/ul>\n\n\n\n Also, you must provide the doctor with the list of all medicines and supplements you are taking. As Wegovy can slow how fast the stomach empties, it may interact with some medicines, especially those taking diabetic medicines like insulin or sulfonylurea ^{4<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} \n In patients on diabetes medications, adjustments of certain ongoing medicines are essential to prevent hypoglycaemia as glucose levels begin to improve. A very commonly prescribed class of drugs, DPP-IV inhibitors, drugs ending with the name \u2018-gliptin\u2019, need to be stopped when starting any GLP1-RA drugs like Wegovy.<\/p>\nDr. Mikhil Kothari, MBBS \| PG Dip. Clinical Endocrinology & Diabetes (RCP, UK)<\/a><\/strong><\/cite><\/blockquote>\n\n\n\n *Also Read:* *Can Wegovy Cause Hair Loss? Here\u2019s What You Should Know<\/a><\/em><\/strong><\/p>\n\n\n\n* <\/span>Wegovy for Heart Health<\/strong><\/span><\/h2>\n\n\n\n Wegovy may not only help with weight loss but it could also protect your heart.\u00a0<\/p>\n\n\n\n It can reduce the risk of heart disease, especially in people with obesity, by lowering body weight and waist size. Losing excess fat can ease strain on the heart and reduce the risk of blocked blood vessels. Research also suggests it may have direct effects on the heart, that help keep the heart and blood vessels healthy.\u00a0<\/p>\n\n\n\n A large study ^{1<\/sup><\/a> called SELECT followed over 17,000 adults who were obese or overweight and had existing heart disease. Those who took Wegovy 2.4 mg once a week had a 20 percent lower risk of heart attack, stroke, or heart-related death. This benefit was observed even in people without diabetes. However, this trial studied secondary cardiovascular prevention, i.e. in people who already had heart disease. There is no current evidence for primary prevention, that is, direct risk reduction in people without existing heart disease. Nonetheless, its positive effects on insulin sensitivity and obesity are proven, which indirectly benefit the heart.\u00a0<\/p>\n\n\n\n} *Also Read:* *Wegovy vs Ozempic: Differences, Uses, Dosage, Side Effects and More!<\/a> \u00a0<\/em><\/strong><\/p>\n\n\n\n* <\/span>When to See a Doctor?<\/strong><\/span><\/h2>\n\n\n\n You must see your doctor right away if you notice the following on taking Wegovy injection.\u00a0<\/p>\n\n\n\n \n Symptoms such as fever, nonstop vomiting, strong stomach or back pain, yellow eyes or skin, or blurry vision.\u00a0<\/li>\n\n\n\n Serious signs that may include allergic reactions, fast heartbeat, mood changes, or difficulty breathing.\u00a0<\/li>\n\n\n\n If you feel dizzy, very tired, or notice swelling.\u00a0<\/li>\n<\/ul>\n\n\n\n You must follow up regularly as recommended by your doctor<\/a><\/strong> to monitor the health condition while on Wegovy treatment ^{4<\/sup><\/a>.\u00a0<\/p>\n\n\n\n} *Also Read:* *Wegovy Diet Plan: Complete Food Guide, Side Effect Management & Meal Ideas<\/a><\/em><\/strong><\/p>\n\n\n\n* <\/span>Conclusion<\/strong><\/span><\/h2>\n\n\n\n Wegovy may be helpful to support those struggling with overweight and obesity issues. It is approved for long-term weight management in people with obesity or those who are overweight with other health problems. It\u2019s not a quick fix, but when it\u2019s combined with proper diet and physical activity, it may give good results over time. It may also improve insulin sensitivity and lower weight-related health risks. It should be taken only under medical advice, with dose increased slowly and regular checks for stomach-related side effects, as well as to rule out certain health problems like thyroid cancers. Regular follow-up is also needed so it may work well and support your fight against obesity and related risks.\u00a0<\/p>\n\n\n\n *Also Read:* *Is Mounjaro Approved for Weight Loss? Here\u2019s What Our Endocrinologist Says<\/a><\/em><\/strong><\/p>\n\n\n\n* <\/span>Frequently Asked Questions (FAQs)<\/strong><\/span><\/h2>\n\n\n\nIs Wegovy safe for PCOS?<\/strong><\/strong> Wegovy is used for PCOS under medical supervision. Few Wegovy side effects like nausea or vomiting may occur. It may help manage weight and support better insulin resistance and menstrual cycle regularity ^{19<\/sup><\/a>.\u00a0<\/p> <\/div>} \u00a0What are the worst side effects of Wegovy?<\/strong><\/strong> The worst side effects of Wegovy may be swelling of the pancreas, severe allergic reactions, and gallbladder problems. Sometimes kidney problems can occur, and those taking certain diabetes medicines can get very low blood sugar. Although these are not common, they may affect some people ^{4<\/sup><\/a>.\u00a0<\/p> <\/div>} Is Wegovy available in India?<\/strong><\/strong> Yes. Wegovy became available in India in June\u202f2025 and is now purchasable at select pharmacies.\u00a0<\/p> <\/div> Can I stop Wegovy after weight loss?<\/strong><\/strong> No, you should not stop Wegovy by yourself. If you stop, you may regain much of the weight you lost and improvements in blood sugar, cholesterol, and blood pressure may reduce. If you want to stop or have any concerns, your doctor will advise you on what to do ^{20<\/sup><\/a>.\u00a0<\/p> <\/div> <\/div>\n\n\n\n} <\/span>References<\/strong><\/span><\/h2>\n\n\n\n\n A. Michael Lincoff, Kirstine Brown\u2010Frandsen, Colhoun HM, Deanfield J, Emerson SS, Sille Esbjerg, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine [Internet]. 2023 Nov 11;389(24). Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2307563<\/a>\u00a0<\/li>\n\n\n\n Olukorode JO, Orimoloye DA, Nwachukwu NO, Onwuzo CN, Oloyede PO, Temiloluwa Fayemi, et al. Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders. Cureus [Internet]. 2024 Oct 21;16(10). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11579408\/<\/a>\u00a0<\/li>\n\n\n\n GLP-1 medicines for weight loss and diabetes: what you need to know [Internet]. GOV.UK. 2025. Available from: https:\/\/www.gov.uk\/government\/publications\/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know\/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know<\/a>\u00a0<\/li>\n\n\n\n HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf<\/a>\u00a0<\/li>\n\n\n\n Research C for DE and. New Drug Therapy Approvals 2022. FDA [Internet]. 2023; Available from: https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/new-drug-therapy-approvals-2022<\/a>\u00a0<\/li>\n\n\n\n Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine [Internet]. 2023 May 25;70(1):jim-2021-001952. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8717485\/<\/a>\u00a0<\/li>\n\n\n\n Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism [Internet]. 2022 Oct 18;25(1). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10092086\/<\/a>\u00a0<\/li>\n\n\n\n Patoulias D, Popovic DS, Stoian AP, Janez A, Sahebkar A, Rizzo M. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. Journal of Diabetes and Its Complications [Internet]. 2023 Jun 7;37(8):108529. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37301063\/<\/a>\u00a0\u00a0<\/li>\n\n\n\n Ryan N, Savulescu J. The Ethics of Ozempic and Wegovy. Journal of Medical Ethics [Internet]. 2025 Jan 23;jme-2024-110374. Available from: https:\/\/jme.bmj.com\/content\/medethics\/early\/2025\/01\/23\/jme-2024-110374.full.pdf<\/a>\u00a0<\/li>\n\n\n\n FDA. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight [Internet]. FDA. 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or#:~:text=Today%2C%20the%20U.S.%20Food%20and%20Drug%20Administration%20approved,with%20cardiovascular%20disease%20and%20either%20obesity%20or%20overweight<\/a>\u00a0<\/li>\n\n\n\n OZEMPIC HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209637s025lbl.pdf<\/a>\u00a0\u00a0<\/li>\n\n\n\n Kommu S, Whitfield P. Semaglutide [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603723\/<\/a>\u00a0\u00a0<\/li>\n\n\n\n Wilding JPH, Batterham RL, Calanna S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine [Internet]. 2021 Feb 10;384(11):989\u20131002. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2032183<\/a>\u00a0\u00a0\u00a0<\/li>\n\n\n\n Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine [Internet]. 2024 May 13;30(30):1\u20139. Available from: https:\/\/www.nature.com\/articles\/s41591-024-02996-7<\/a>\u00a0<\/li>\n\n\n\n Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open [Internet]. 2022 Sep 19;5(9):e2231982. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9486455\/<\/a>\u00a0<\/li>\n\n\n\n Plank J. A Heavy Price: the Economic and Social Costs of GLP-1 Weight Loss Drugs [Internet]. Equilibrium. 2025. Available from: https:\/\/equilibriumecon.wisc.edu\/2025\/01\/09\/a-heavy-price-the-economic-and-social-costs-of-glp-1-weight-loss-drugs\/<\/a>\u00a0<\/li>\n\n\n\n Central Drugs Standard Control Organisation (CDSCO). Recommendations of the Subject Expert Committee (Endocrinology & Metabolism) meeting held on 13 August 2024 [Internet]. New Delhi: CDSCO; 2024 Aug 13 [cited 2025 Jun 17]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Endocrinology%20%26%20Metabolism%2013.08.2024.pdf<\/a>\u00a0<\/li>\n\n\n\n Central Drugs Standard Control Organisation (CDSCO). Recommendations of the Subject Expert Committee (Endocrinology & Metabolism) meeting held on 24 July 2024 [Internet]. New Delhi: CDSCO; 2024 Jul 24 [cited 2025 Jun 17]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendation%20Endocrinology%20&%20Metabolism%20dated%2024.07.2024.pdf<\/a>\u00a0<\/li>\n\n\n\n Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine [Internet]. 2023 Jan 1;12(18):5921. Available from: https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5921#:~:text=In%20conclusion%2C%20treatment%20with%20semaglutide<\/a>\u00a0\u00a0<\/li>\n\n\n\n Wilding JPH. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism [Internet]. 2022 May 19;24(8):1553\u201364. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35441470\/<\/a>\u00a0\u00a0<\/li>\n<\/ol>\n\n\n\n \u00a0Disclaimer<\/em><\/strong>: The information provided here is for educational\/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.<\/em><\/p>\n<\/body><\/html>\n *\r\n* \r\n \r\n $\"Likes\"$ \r\n <\/a>\r\n <\/span>\r\n<\/div> \r\n \r\n $\"Dislikes\"$ \r\n <\/a>\r\n <\/span>\r\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Introduction Obesity is becoming a common health issue around the world. Experts say that by 2035, more than half of the global population may be overweight or obese. Having a high body weight was linked to around 4 million deaths worldwide in 20151.\u00a0 To help manage this problem, doctors now use a group of medicines [\u2026]","protected":false},"author":176,"featured_media":248900,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_wp_rev_ctl_limit":""},"categories":[14037],"tags":[13847,13846],"acf":[],"_embedded":{"wp:featuredmedia":[{"source_url":"https:\/\/blog-images-1.pharmeasy.in\/blog\/production\/wp-content\/uploads\/2025\/08\/19094941\/wegovy-semaglutide.webp"}]},"_links":{"self":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/248778"}],"collection":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/users\/176"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/comments?post=248778"}],"version-history":[{"count":7,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/248778\/revisions"}],"predecessor-version":[{"id":275693,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/248778\/revisions\/275693"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media\/248900"}],"wp:attachment":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media?parent=248778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/categories?post=248778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/tags?post=248778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}